On August 23, 2021 LUNGevity Foundation, the nation’s leading lung cancer-focused nonprofit organization, reported that it is partnering with The Hamoui Foundation to offer a new lung cancer research award program (Press release, LUNGevity Foundation, AUG 23, 2021, View Source [SID1234586823]). The award supports research that will change RET-positive lung cancer into a chronic or curable condition. This will be transformative for the approximately 1%-2% of people with non-small cell lung cancer with the RET driver mutation. Funding for this award is being provided by The Hamoui Foundation, while LUNGevity will provide research infrastructure and scientific expertise. Funded research projects should have a direct impact on the outcomes of patients with advanced RET-positive lung cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Hamoui Foundation/LUNGevity award may be for a maximum of $1 million: $500,000 per year for up to two years. Projects funded through this award will have direct clinical implications in 1-2 years.
"In 2020, the United States Food and Drug Administration approved two targeted therapies for RET fusion-positive lung cancer. These new drugs have greatly impacted the treatment of RET+ lung cancer. However, like all targeted therapies, we are seeing resistance develop to these new drugs. Through this partnership with The Hamoui Foundation, we hope to address the What’s next after these drugs," explained Dr. Upal Basu Roy, Executive Director of Research at LUNGevity.
"We’re excited to partner with LUNGevity on research that will improve outcomes for patients with RET+ lung cancer," said Omaima Salous, co-founder of the Hamoui Foundation. "As a mother of young children and a survivor living with RET+ lung cancer, I know how vital this research is for our community."
The RFA for this award is available on the LUNGevity website at www.LUNGevity.org/apply-for-award and on the proposalCentral website at proposalcentral.com.
Letters of intent for the award must be submitted by September 17, 2021.